TriSalus Life Sciences (TLSI) Competitors $4.66 +0.07 (+1.42%) As of 02:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSI vs. IRMD, BBNX, EMBC, TNDM, AXGN, SIBN, CLPT, BVS, AVNS, and ZIMVShould you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include iRadimed (IRMD), Beta Bionics (BBNX), Embecta (EMBC), Tandem Diabetes Care (TNDM), AxoGen (AXGN), SiBone (SIBN), ClearPoint Neuro (CLPT), Bioventus (BVS), Avanos Medical (AVNS), and ZimVie (ZIMV). These companies are all part of the "medical equipment" industry. TriSalus Life Sciences vs. Its Competitors iRadimed Beta Bionics Embecta Tandem Diabetes Care AxoGen SiBone ClearPoint Neuro Bioventus Avanos Medical ZimVie iRadimed (NASDAQ:IRMD) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations. Does the media favor IRMD or TLSI? In the previous week, iRadimed had 4 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 7 mentions for iRadimed and 3 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.83 beat iRadimed's score of 0.34 indicating that TriSalus Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TriSalus Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, IRMD or TLSI? iRadimed has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Do insiders & institutionals have more ownership in IRMD or TLSI? 92.3% of iRadimed shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 36.8% of iRadimed shares are owned by company insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is IRMD or TLSI more profitable? iRadimed has a net margin of 26.61% compared to TriSalus Life Sciences' net margin of -86.61%. iRadimed's return on equity of 23.30% beat TriSalus Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets iRadimed26.61% 23.30% 20.62% TriSalus Life Sciences -86.61%N/A -116.50% Which has preferable earnings & valuation, IRMD or TLSI? iRadimed has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiRadimed$73.24M12.83$19.23M$1.6245.59TriSalus Life Sciences$29.43M7.89-$30.05M-$1.18-3.94 Do analysts rate IRMD or TLSI? iRadimed presently has a consensus price target of $72.00, indicating a potential downside of 2.51%. TriSalus Life Sciences has a consensus price target of $10.90, indicating a potential upside of 134.16%. Given TriSalus Life Sciences' higher probable upside, analysts plainly believe TriSalus Life Sciences is more favorable than iRadimed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iRadimed 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00TriSalus Life Sciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00 SummaryiRadimed beats TriSalus Life Sciences on 12 of the 16 factors compared between the two stocks. Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSI vs. The Competition Export to ExcelMetricTriSalus Life SciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$232.15M$10.56B$6.06B$10.50BDividend YieldN/A1.90%5.73%4.82%P/E Ratio-3.9421.0985.4527.28Price / Sales7.8929.68593.90134.93Price / CashN/A25.5625.7730.18Price / Book-5.613.4412.696.76Net Income-$30.05M$210.63M$3.32B$276.46M7 Day Performance-2.62%-1.20%0.54%0.87%1 Month Performance5.08%1.00%9.47%8.20%1 Year Performance7.26%-6.27%79.06%43.74% TriSalus Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSITriSalus Life Sciences2.5556 of 5 stars$4.66+1.4%$10.90+134.2%+8.3%$232.15M$29.43M-3.94106IRMDiRadimed4.5682 of 5 stars$71.16+1.6%$72.00+1.2%+43.6%$905.16M$73.24M43.93110BBNXBeta Bionics1.8155 of 5 stars$19.87+0.1%$23.33+17.4%N/A$863.75M$65.12M0.00294EMBCEmbecta4.6729 of 5 stars$14.11+0.8%$19.00+34.7%+4.1%$825.22M$1.10B9.872,100Positive NewsTNDMTandem Diabetes Care4.1859 of 5 stars$12.14+3.0%$22.44+84.8%-62.6%$820.29M$1.00B-3.932,650AXGNAxoGen2.9469 of 5 stars$17.84+3.4%$25.75+44.3%+6.0%$794.18M$203.27M-178.38450SIBNSiBone3.8298 of 5 stars$14.72+3.9%$23.67+60.8%+13.8%$635.02M$167.18M-26.29350CLPTClearPoint Neuro0.6797 of 5 stars$21.79+1.0%$19.67-9.7%+126.3%$619.49M$31.39M-26.90110Gap DownHigh Trading VolumeBVSBioventus1.3428 of 5 stars$6.69+1.1%N/AN/A$553.12M$564.14M13.321,200News CoverageAVNSAvanos MedicalN/A$11.57+0.3%N/A-51.9%$536.85M$687.80M-1.152,227Analyst ForecastZIMVZimVie1.1519 of 5 stars$18.94+0.2%$17.75-6.3%+18.6%$534.32M$443.40M-27.061,770 Related Companies and Tools Related Companies iRadimed Competitors Beta Bionics Competitors Embecta Competitors Tandem Diabetes Care Competitors AxoGen Competitors SiBone Competitors ClearPoint Neuro Competitors Bioventus Competitors Avanos Medical Competitors ZimVie Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSI) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
